Download PDF
Synthesis 1999; 1999(5): 769-774
DOI: 10.1055/s-1999-3458
paper
© Georg Thieme Verlag, Rüdigerstr. 14, 70469 Stuttgart, Germany. All rights reserved. This journal, including all individual contributions and illustrations published therein, is legally protected by copyright for the duration of the copyright period. Any use, exploitation or commercialization outside the narrow limits set by copyright legislation, without the publisher's consent, is illegal and liable to criminal prosecution. This applies in particular to photostat reproduction, copying, cyclostyling, mimeographing or duplication of any kind, translating, preparation of microfilms, and electronic data processing and storage.

A Convergent Synthesis of CGS23305, A Thromboxane Synthase Inhibitor

Andrew T. Bach* , John A. Carlson, Peter P. Giannousis
  • *Chemical Development, Novartis Pharmaceuticals Corporation, 564 Morris Avenue, Summit, New Jersey 07901, USA; Fax +1(9 73)7 81 21 88; E-mail: peter.giannousis@pharma.novartis.com
Further Information

Publication History

Publication Date:
31 December 1999 (online)

  PDF Download  Permissions and Reprints All articles of this category

A convergent synthesis of CGS23305 was discovered. The route to the pyridine aldehyde intermediate 5 was reduced from four to two steps. The pyridine aldehyde was converted to the key pyridine aldehyde ester intermediate 7 via Miachel Addition of the N,N-diethylenamine 6 to ethyl acrylate. A Wittig alkenation using the multifunctional moiety 19 completed the carbons keleteon assembly. Hydrogenation and hydrolysis afforded CGS23305 in 44% overall yield from 14 (6 steps).

convergent synthesis - pyridine - aldehydes - thromboxane inhibitor